RESUMEN
The quick dynamic insulin sensitivity test (DISTq) can yield an insulin sensitivity result immediately after a 30-min clinical protocol. The test uses intravenous boluses of 10 g glucose and 1 U insulin at t = 1 and 11 min, respectively, and measures glucose levels in samples taken at t = 0, 10, 20, and 30 min. The low clinical cost of the protocol is enabled via robust model formulation and a series of population-derived relationships that estimate insulin pharmacokinetics as a function of insulin sensitivity (SI). Fifty individuals underwent the gold standard euglycaemic clamp (EIC) and DISTq within an eight-day period. SI values from the EIC and two DISTq variants (four-sample DISTq and two-sample DISTq30) were compared with correlation, Bland-Altman and receiver operator curve analyses. DISTq and DISTq30 correlated well with the EIC [R = 0.76 and 0.75, and receiver operator curve c-index = 0.84 and 0.85, respectively]. The median differences between EIC and DISTq/DISTq30 SI values were 13% and 22%, respectively. The DISTq estimation method predicted individual insulin responses without specific insulin assays with relative accuracy and thus high equivalence to EIC SI values was achieved. DISTq produced very inexpensive, relatively accurate immediate results, and can thus enable a number of applications that are impossible with established SI tests.
Asunto(s)
Técnica de Clampeo de la Glucosa/métodos , Prueba de Tolerancia a la Glucosa/métodos , Resistencia a la Insulina/fisiología , Modelos Biológicos , Adulto , Anciano , Femenino , Glucosa/administración & dosificación , Glucosa/metabolismo , Humanos , Insulina/metabolismo , Ácido Láctico , Masculino , Persona de Mediana Edad , Curva ROCRESUMEN
The objective was to validate the methodology for the dynamic insulin sensitivity and secretion test (DISST) and to demonstrate its potential in clinical and research settings. One hundred twenty-three men and women had routine clinical and biochemical measurements, an oral glucose tolerance test, and a DISST. For the DISST, participants were cannulated for blood sampling and bolus administration. Blood samples were drawn at t = 0, 10, 15, 25, and 35 minutes for measurement of glucose, insulin, and C-peptide. A 10-g bolus of intravenous glucose at t = 5 minutes and 1 U of intravenous insulin immediately after the t = 15 minute sample were given. Fifty participants also had a hyperinsulinemic-euglycemic clamp. Relationships between DISST insulin sensitivity (SI) and the clamp, and both DISST SI and secretion and other metabolic variables were measured. A Bland-Altman plot showed little bias in the comparison of DISST with the clamp, with DISST underestimating the glucose clamp by 0.1·10(-2)·mg·L·kg(-1)·min(-1)·pmol(-1) (90% confidence interval, -0.2 to 0). The correlation between SI as measured by DISST and the clamp was 0.82; the c unit for the receiver operating characteristic curve analysis for the 2 tests was 0.96. Metabolic variables showed significant correlations with DISST SI and the second phase of insulin release. The DISST also appears able to distinguish different insulin secretion patterns in individuals with identical SI values. The DISST is a simple, dynamic test that compares favorably with the clamp in assessing SI and allows simultaneous assessment of insulin secretion. The DISST has the potential to provide even more information about the pathophysiology of diabetes than more complicated tests.
Asunto(s)
Glucemia/metabolismo , Diabetes Mellitus/diagnóstico , Resistencia a la Insulina , Insulina/metabolismo , Adulto , Anciano , Diabetes Mellitus/sangre , Femenino , Glucosa/administración & dosificación , Técnica de Clampeo de la Glucosa , Humanos , Insulina/sangre , Secreción de Insulina , Masculino , Persona de Mediana EdadRESUMEN
OBJECTIVE: Untreated Cushing's syndrome (CS) is associated with significant morbidity and mortality. However, recent operative series suggest low morbidity and mortality for CS, whereas population-based surveys report elevated mortality rates. We investigated the mortality and morbidity of CS in New Zealand. DESIGN: A nationwide retrospective survey of patients with CS between 1960 and 2005 managed at the four main endocrinology services. PATIENTS: A total of 253 patients with CS were identified, excluding adrenal carcinoma and malignant ectopic CS. MEASUREMENTS; The primary outcome was the standardized mortality ratio (SMR), comparing the observed number of deaths with the expected number for the population matched for age, sex and duration of follow-up. Secondary outcomes were the change in prevalence of co-morbidities at presentation and at final follow-up. RESULTS: The approximate prevalence and incidence of CS was 79/million and 1·8/million/y. The mean age at presentation was 39 year, and median duration of follow-up was 6·4 year (range 0-46). Overall, 89% achieved biochemical cure at last follow-up, with >90% achieving biochemical cure for CS from adrenal adenoma and pituitary causes. Thirty-six patients died during follow-up compared with 8·8 expected deaths (SMR 4·1, 95%CI 2·9-5·6). While hypertension, sexual dysfunction, myopathy and mild psychiatric illness were significantly reduced after treatment, hypertension, diabetes mellitus, moderate or major psychiatric illness, and osteoporosis were common at final follow-up. CONCLUSION: CS is associated with both high mortality and a high prevalence of co-morbidities, even when biochemical cure rates are between 80% and 90%.
Asunto(s)
Síndrome de Cushing/epidemiología , Síndrome de Cushing/mortalidad , Adolescente , Adulto , Anciano , Niño , Preescolar , Síndrome de Cushing/patología , Femenino , Humanos , Masculino , Persona de Mediana Edad , Nueva Zelanda/epidemiología , Estudios Retrospectivos , Adulto JovenRESUMEN
Insulin sensitivity (SI) is useful in the diagnosis, screening and treatment of diabetes. However, most current tests cannot provide an accurate, immediate or real-time estimate. The DISTq method does not require insulin or C-peptide assays like most SI tests, thus enabling real-time, low-cost SI estimation. The method uses a posteriori parameter estimations in the absence of insulin or C-peptide assays to simulate accurate, patient-specific, insulin concentrations that enable SI identification. Mathematical functions for the a posteriori parameter estimates were generated using data from 46 fully sampled DIST tests (glucose, insulin and C-peptide). SI values found using the DISTq from the 46 test pilot cohort and a second independent 218 test cohort correlated R=0.890 and R=0.825, respectively, to the fully sampled (including insulin and C-peptide assays) DIST SI metrics. When the a posteriori insulin estimation functions were derived using the second cohort, correlations for the pilot and second cohorts reduced to 0.765 and 0.818, respectively. These results show accurate SI estimation is possible in the absence of insulin or C-peptide assays using the proposed method. Such estimates may only need to be generated once and then used repeatedly in the future for isolated cohorts. The reduced correlation using the second cohort was due to this cohort's bias towards low SI insulin resistant subjects, limiting the data set's ability to generalise over a wider range. All the correlations remain high enough for the DISTq to be a useful test for a number of clinical applications. The unique real-time results can be generated within minutes of testing as no insulin and C-peptide assays are required and may enable new clinical applications.
Asunto(s)
Resistencia a la Insulina , Modelos Biológicos , Glucemia/análisis , Péptido C/sangre , Estudios de Cohortes , Simulación por Computador , Diabetes Mellitus Tipo 2/sangre , Diabetes Mellitus Tipo 2/diagnóstico , Femenino , Técnica de Clampeo de la Glucosa , Prueba de Tolerancia a la Glucosa , Humanos , Insulina/sangre , Proyectos PilotoRESUMEN
BACKGROUND: Numerous tests have been developed to estimate insulin sensitivity (SI). However, most of the established tests are either too expensive for widespread application or do not yield reliable results. The dynamic insulin sensitivity and secretion test (DISST) uses assays of glucose, insulin, and C-peptide from nine samples to quantify SI and endogenous insulin secretion (UN) at a comparatively low cost. The quick dynamic insulin sensitivity test has shown that the DISST SI values are robust to significant assay omissions. METHODS: Eight DISST-based variations of the nine-sample assay regimen are proposed to investigate the effects of assay omission within the DISST-based framework. SI and UN were identified using the fully-sampled DISST and data from 218 nine-sample tests undertaken in 74 female individuals with elevated diabetes risk. This same data was then used with appropriate assay omissions to identify SI and UN with the eight DISST-based assay variations. RESULTS: Median intraprocedure proportional difference between SI values from fully-sampled DISST and the DISST-based variants was in the range of -17.9 to 7.8%. Correlations were in the range of r = 0.71 to 0.92 with the highest correlations between variants with the greatest commonality with the nine-sample DISST. Metrics of UN correlated relatively well between tests when C-peptide was assayed (r = 0.72 to 1) but were sometimes not well estimated when samples were not assayed for C-peptide (r = -0.14 to 0.75). CONCLUSIONS: The DISST-based spectrum offers a series of tests with very distinct compromises of information yield, accuracy, assay cost, and clinical intensity. Thus, the spectrum of tests has the potential to enable researchers to better allocate funds by selecting an optimal test configuration for their particular application.
Asunto(s)
Análisis Químico de la Sangre/métodos , Glucemia/análisis , Péptido C/análisis , Resistencia a la Insulina , Insulina/sangre , Análisis Químico de la Sangre/economía , Femenino , Humanos , Reproducibilidad de los ResultadosRESUMEN
BACKGROUND: Insulin resistance is a significant risk factor in the pathogenesis of type 2 diabetes. This article presents pilot study results of the dynamic insulin sensitivity and secretion test (DISST), a high-resolution, low-intensity test to diagnose insulin sensitivity (IS) and characterize pancreatic insulin secretion in response to a (small) glucose challenge. This pilot study examines the effect of glucose and insulin dose on the DISST, and tests its repeatability. METHODS: DISST tests were performed on 16 subjects randomly allocated to low (5 g glucose, 0.5 U insulin), medium (10 g glucose, 1 U insulin) and high dose (20 g glucose, 2 U insulin) protocols. Two or three tests were performed on each subject a few days apart. RESULTS: Average variability in IS between low and medium dose was 10.3% (p=.50) and between medium and high dose 6.0% (p=.87). Geometric mean variability between tests was 6.0% (multiplicative standard deviation (MSD) 4.9%). Geometric mean variability in first phase endogenous insulin response was 6.8% (MSD 2.2%). Results were most consistent in subjects with low IS. CONCLUSIONS: These findings suggest that DISST may be an easily performed dynamic test to quantify IS with high resolution, especially among those with reduced IS.
Asunto(s)
Glucemia/metabolismo , Diabetes Mellitus Tipo 2/diagnóstico , Prueba de Tolerancia a la Glucosa , Glucosa , Resistencia a la Insulina , Insulina , Páncreas/metabolismo , Proyectos de Investigación , Adulto , Biomarcadores/sangre , Péptido C/sangre , Diabetes Mellitus Tipo 2/sangre , Diabetes Mellitus Tipo 2/fisiopatología , Estudios de Factibilidad , Femenino , Humanos , Insulina/sangre , Masculino , Persona de Mediana Edad , Nueva Zelanda , Proyectos Piloto , Valor Predictivo de las Pruebas , Reproducibilidad de los Resultados , Factores de Tiempo , Adulto JovenRESUMEN
Insulin sensitivity (SI) estimation has numerous uses in medical and clinical situations. However, highresolution tests that are useful for clinical diagnosis and monitoring are often too intensive, long and costly for regular use. Simpler tests that mitigate these issues are not accurate enough for many clinical diagnostic or monitoring scenarios. The gap between these tests presents an opportunity for new approaches. The quick dynamic insulin sensitivity test (DISTq) utilises the model-based DIST test protocol and a series of population estimates to eliminate the need for insulin or C-peptide assays to enable a high resolution, low-intensity, real-time evaluation of SI. The method predicts patient specific insulin responses to the DIST test protocol with enough accuracy to yield a useful clinical insulin sensitivity metric for monitoring of diabetes therapy. The DISTq method replicated the findings of the fully sampled DIST test without the use of insulin or C-peptide assays. Correlations of the resulting SI values was R=0.91. The method was also compared to the euglycaemic hyperinsulinaemic clamp (EIC) in an in-silico Monte-Carlo analysis and showed a good ability to re-evaluate SI(EIC) (R=0.89), compared to the fully sampled DIST (R=0.98) Population-derived parameter estimates using a-posteriori population-based functions derived from DIST test data enables the simulation of insulin profiles that are sufficiently accurate to estimate SI to a relatively high precision. Thus, costly insulin and C-peptide assays are not necessary to obtain an accurate, but inexpensive, real-time estimate of insulin sensitivity. This estimate has enough resolution for SI prediction and monitoring of response to therapy. In borderline cases, re-evaluation of stored (frozen) blood samples for insulin and C-peptide would enable greater accuracy where necessary, enabling a hierarchy of tests in an economical fashion.